Pre-clinical research agreement announced to support global biomedical community

An agreement between Crown Bioscience (CrownBio) and The Jackson Laboratory (JAX) has been announced to improve the development and accessibility of innovative research models and pre-clinical services to the global biomedical research community.

Under the terms of the agreement CrownBio will advance the use of JAX Mice in client research studies and will increase the use and improve access of JAX research models. JAX research scientists will have access to CrownBio’s pre-clinical contract laboratory services, which will provide them with additional resources and facilities in which to continue the search for cures for cancer and other diseases.

“The agreement with JAX heralds a significant step forward for oncology and immune-oncology pre-clinical research,” said Jean-Pierre Wery, PhD, CEO of CrownBio. “The utilisation of JAX’s scientific-leading humanised and translational models in combination with our PDX technology platforms will ensure the greatest potential for translatable drug development.”

“JAX’s mission is to empower the global biomedical community in our shared quest to improve human health. By harnessing our complementary strengths, this agreement allows us to propel scientific research and drug discovery globally by improving accessibility to the most advanced and highest quality pre-clinical research models and services,” added Auro Nair, PhD, president of JAX Mice, Clinical & Research Services. “Additionally, JAX research teams will be able to advance basic biological discoveries to therapies much more rapidly by utilising the world’s largest collection of PDX and cell-line models and services from CrownBio.”